CD8A and early-onset autosomal dominant Alzheimer disease: Additionally, ACD49d Ab therapy has the potential to beneficial in other age-associated neurodegenerative diseases associated with CD8+ T cell infiltration, such as Alzheimer’s disease and Parkinson’s disease [59, 60].